drugset / Trial / NCT00685802

Fasted Bioavailability Study of Cilostazol Tablets, 50mg

NCT00685802

Phase 1 Completed 32 enrolled Mutual Pharmaceutical Company, Inc.
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to evaluate and compare the relative bioavailability of a test formulation of cilostazol tablets to an equivalent dose of Pletal® (cilostazol) tablets after a single oral dose administered under fasting conditions.

Timeline

Start
2004-06
Primary completion
2004-07
Completion
2004-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cilostazol Small molecule 100 mg Oral

Indications

No indication recorded.